Therapy of growth disorders

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 1, 2011, Pages 3-8

  Ali, Omar ^a   Wyatt, David ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Growth; growth hormone therapy; insulin like growth factor 1; Prader Willi syndrome; short stature

Indexed keywords

AROMATASE INHIBITOR; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C;

ARTICLE; BODY COMPOSITION; BODY HEIGHT; BONE DENSITY; CHRONIC DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GROWTH DISORDER; HORMONAL THERAPY; HUMAN; OFF LABEL DRUG USE; PATIENT SELECTION; PRADER WILLI SYNDROME; RECOMMENDED DRUG DOSE; SHORT STATURE;

BODY HEIGHT; CHILD; DIAGNOSTIC TECHNIQUES, ENDOCRINE; GROWTH CHARTS; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PRADER-WILLI SYNDROME;

EID: 78650831355     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328341f873     Document Type: Article

References (52)

1. Haghshenas Z, Sotoudeh K, Karamifar H, et al. The role of insulin like growth factor (IGF)-1 and IGF-binding protein-3 in diagnosis of growth hormone deficiency in short stature children. Indian J Pediatr 2009; 76:699-703.
2. Tenenbaum-Rakover Y, Hujeirat Y, Admoni O, et al. Can auxology, IGF-I and IGFBP-3 measurements followed by MRI and genetic tests replace GH stimulation tests in the diagnosis of GH deficiency in children? J Pediatr Endocrinol Metab 2010; 23:387-394.
3. Obara-Moszyńska M, Kedzia A, Korman E, Niedziela M. Usefulness of growth hormone (GH) stimulation tests and IGF-I concentration measurement in GH deficiency diagnosis. J Pediatr Endocrinol Metab 2008; 21:569-579.
4. Wyatt D, Parker KL, Kemp SF, et al. The evaluation and followup of children referred to pediatric endocrinologists for short stature. Int J Pediatr Endocrinol 2010; 2010:652013.
5. Miller BS, Shulman D, Shillington A, et al. Consensus and discordance in the management of growth hormone-treated patients: results of a Knowledge, Attitudes, Beliefs, and Practices (KABP) Survey. Int J Pediatr Endocrinol 2010; 2010: 891571.
6. Silvers JB, Marinova D, Mercer MB, et al. A national study of physician recommendations to initiate and discontinue growth hormone for short stature. Pediatrics 2010; 126:468-476.
7. Simon D, Bechtold S. Effects of growth hormone treatment on growth in children with juvenile idiopathic arthritis. Horm Res 2009; 72 (Suppl 1):55-59.
8. Cody JD, Semrud-Clikeman M, Hardies LJ, et al. Growth hormone benefits children with 18q deletions. Am J Med Genet A 2005; 137:9-15.
9. Guevarra FM, Nimkarn S, New MI, Lin-Su K. Long-term growth hormone therapy in an adolescent boy with 45,X/46,XidicY(p11). J Pediatr 2009; 155:752-755; e1-e3.
10. Polgreen LE, Miller BS. Growth patterns and the use of growth hormone in the mucopolysaccharidoses. J Pediatr Rehabil Med 2010; 3:25-38.
11. Polgreen LE, Plog M, Schwender JD, et al. Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44:279-285.
12. Rothenbühler A, Piquard C, Gueorguieva I, et al. Near normalization of adult height and body proportions by growth hormone in pycnodysostosis. J Clin Endocrinol Metab 2010; 95:2827-2831.
13. Myrelid A, Bergman S, Elfvik Strömberg M, et al. Late effects of early growth hormone treatment in Down syndrome. Acta Paediatr 2010; 99:763-769.
14. Sipilä I, Sintonen H, Hietanen H, et al. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome. Acta Paediatr 2010. [Epub ahead of print]
15. Grugni G, Crinò A, Bosio L, et al., Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology (ISPED). The Italian National Survey for Prader-Willi syndrome: an epidemiologic study. Am J Med Genet A 2008; 146:861-872.
16. Nyunt O, Harris M, Hughes I, et al. Benefit of early commencement of growth hormone therapy in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 2009; 22:1151-1158.
17. Festen DA, de Lind van Wijngaarden R, van Eekelen M, et al. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2008; 69:443-451.
18. Carrel AL, Myers SE, Whitman BY, et al. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2010; 95:1131-1136.
19. Cohen P, Rogol AD, Howard CP, et al. American Norditropin Study Group. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007; 92:2480-2486.
20. Marchisotti FG, Jorge AA, Montenegro LR, et al. Comparison between weightbased and IGF-I-based growth hormone (GH) dosing in the treatment of children with GH deficiency and influence of exon 3 deleted GH receptor variant. Growth Horm IGF Res 2009; 19:179-186.
21. Cohen P, Germak J, Rogol AD, et al. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. American Norditropin Study Group. J Clin Endocrinol Metab 2010; 95:2089-2098.
22. Cohen P, Rogol AD, Deal CL, et al. On behalf of the 2007 ISS Consensus Workshop participants 2008. Consensus Guidelines for the diagnosis and treatment of children with idiopathic short stature: a summary statement of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2008; 93:4210-4217.
23. Frindik JP,Morales A, Fowlkes J, et al. Stimulant medication use and response to growth hormone therapy: an NCGS database analysis. Horm Res 2009; 72:160-166.
24. Ross J, Czernichow P, Biller BM, et al., Advisory Panel meeting on the effects of growth hormone. Growth hormone: health considerations beyond height gain. Pediatrics 2010; 125:e906-e918.
25. Abrams P, Boquete H, Fideleff H, et al. GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables. Eur J Endocrinol 2008; 159:825-832.
26. Follin C, Thilén U, Osterberg K, et al. Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab 2010; 95:3726-3735.
27. Puga González B, Ferrández Longás A, Oyarzá bal M, Nosas R, Grupo Colaborativo Español. The effects of growth hormone deficiency and growth hormone replacement therapy on intellectual ability, personality and adjustment in children. Pediatr Endocrinol Rev 2010; 7:328-338.
28. Bechtold S, Dalla Pozza R, Schwarz HP, Simon D. Effects of growth hormone treatment in juvenile idiopathic arthritis: bone and body composition. Horm Res 2009; 72 (Suppl 1):60-64.
29. Bechtold S, Ripperger P, Dalla Pozza R, et al. Dynamics of body composition and bone in patients with juvenile idiopathic arthritis treated with growth hormone. J Clin Endocrinol Metab 2010; 95:178-185.
30. Wales PW, Nasr A, de Silva N, Yamada J. Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst Rev 2010; 6:CD006321. 31 Christensen T, Buckland A, Bentley A, et al. Cost-effectiveness of somatropin for the treatment of short children born small for gestational age. Clin Ther 2010; 32:1068-1082.
31. Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 2010; 14:1-209; iii-iv.
32. Bullinger M, Kołtowska-Häggström M, Sandberg D, et al. Health-related quality of life of children and adolescents with growth hormone deficiency or idiopathic short stature. Part 2: Available results and future directions. Horm Res 2009; 72:74-81
33. Brütt AL, Sandberg DE, Chaplin J, et al. Assessment of health-related quality of life and patient satisfaction in children and adolescents with growth hormone deficiency or idiopathic short stature. Part 1: A critical evaluation of available tools. Horm Res 2009; 72:65-73.
34. Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010; 95:167-177.
35. Arnold JR, Arnold DF, Marland A, et al. GH replacement in patients with nonfunctioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol (Oxf) 2009; 70:435-438.
36. Bogarin R, Steinbok P. Growth hormone treatment and risk of recurrence or progression of brain tumors in children: a review. Childs Nerv Syst 2009; 25:273-279.
37. Carel JC, Butler G. Safety of recombinant human growth hormone. Endocr Dev 2010; 18:40-54.
38. Wilton P, Mattsson AF, Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr 2010; 157:265-270.
39. Popovic V, Mattsson AF, Gaillard RC, et al. serum insulin-like growth factor i (igf-i), igf-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 2010; 95:4449-4454.
40. Laron Z. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatr Endocrinol Rev 2008; 5:766-771.
41. Midyett LK, Rogol AD, Van Meter QL, et al., MS301 Study Group. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab 2010; 95:611-619.
42. Kemp SF. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options. BioDrugs 2009; 23:155-163.
43. Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther 2009; 26:40-54.
44. Collett-Solberg PF, Misra M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008; 93:10-18.
45. Rosenfeld RG. IGF-I therapy in growth disorders. Eur J Endocrinol 2007; 157 (Suppl 1):S57-S60.
46. Hero M, Toiviainen-Salo S, Wickman S, et al. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Miner Res 2010; 25:1536-1543.
47. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752-e762. A thorough review of the topic.
48. Gunther DF, Diekema DS. Attenuating growth in children with profound developmental disability: a new approach to an old dilemma. Arch Pediatr Adolesc Med 2006; 160:1013-1017.
49. Diekema DS, Fost N. Ashley revisited: a response to the critics. Am J Bioeth 2010; 10:30-44.
50. Stein GL. Ashley's Case: the ethics of arresting the growth of children with serious disability. J Soc Work Disabil Rehabil 2010; 9:99-109.
51. Goldworth A. The case: the 'Ashley Treatment' revisited. Commentary: weighing the balance. Camb Q Healthc Ethics 2010; 19:415-416.
52. Allen DB, Kappy M, Diekema D, Fost N. Growth-attenuation therapy: principles for practice. Pediatrics 2009; 123:1556-1561. An excellent review of the indications and methods of growth attenuation.